SMAC-TechnologyTM manufacturing of ADCs

Conventional ADCs generated by chemical conjugation of small molecule toxic drugs to antibodies have numerous liabilities, including limited serum stability and a high degree of heterogeneity with respect to their drug to antibody ratio and functional properties. In order to overcome these limitations, NBE-Therapeutics has developed an enzymatic conjugation platform called SMAC-TechnologyTM (sortase-enzyme mediated antibody conjugation) allowing the site-specific attachment of of small molecule drugs to monoclonal antibodies.

NBE-Therapeutics has fully validated this conjugation technology for the highly efficient manufacturing of site-specifically conjugated and homogeneous next-generation ADCs against relevant cancer cell targets using numerous payload classes.

Overview of SMAC-TechnologyTM conjugation process: